UBS Maintains Neutral on Maravai LifeSciences, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Dan Brennan maintains a Neutral rating on Maravai LifeSciences (NASDAQ:MRVI) and raises the price target from $8.5 to $11.
August 08, 2024 | 1:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS analyst Dan Brennan maintains a Neutral rating on Maravai LifeSciences and raises the price target from $8.5 to $11.
The raised price target from $8.5 to $11 suggests a positive outlook on Maravai LifeSciences' future performance, which could lead to a short-term increase in stock price despite the Neutral rating.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100